IMAGIN MEDICAL INC. (DPD3) - Net Assets
Based on the latest financial reports, IMAGIN MEDICAL INC. (DPD3) has net assets worth €- EUR (≈ $- USD) as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€- ≈ $- USD) and total liabilities (€- ≈ $- USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore DPD3 current and non-current assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
IMAGIN MEDICAL INC. - Net Assets Trend (2021–2022)
This chart illustrates how IMAGIN MEDICAL INC.'s net assets have evolved over time, based on quarterly financial data. Explore IMAGIN MEDICAL INC. cash conversion from operations to assess how effectively this company generates cash.
Annual Net Assets for IMAGIN MEDICAL INC. (2021–2022)
The table below shows the annual net assets of IMAGIN MEDICAL INC. from 2021 to 2022. For live valuation and market cap data, see market value of IMAGIN MEDICAL INC..
| Year | Net Assets | Change |
|---|---|---|
| 2022-09-30 | €-13.34 Million ≈ $-15.59 Million |
-15.55% |
| 2021-09-30 | €-11.54 Million ≈ $-13.49 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to IMAGIN MEDICAL INC.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 249220700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2022)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €21.28 Million | % |
| Total Equity | €-13.34 Million | 100.00% |
IMAGIN MEDICAL INC. Competitors by Market Cap
The table below lists competitors of IMAGIN MEDICAL INC. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CuChi Commercial and Industrial Developing Investment JSC
VN:CCI
|
$6.65K |
|
Grand Vision Media Holdings PLC
LSE:GVMH
|
$7.03K |
|
Taylor Maritime Investments Ltd
LSE:TMI
|
$7.04K |
|
SCG PACKAGING -FGN- BA 1
F:5Y7A
|
$7.12K |
|
Enteq Upstream
LSE:NTQ
|
$6.19K |
|
daVictus plc
LSE:DVT
|
$6.09K |
|
Norofert SA
RO:NRF
|
$5.97K |
|
Renova Energia S.A
SA:RNEW11
|
$5.95K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IMAGIN MEDICAL INC.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -11,540,679 to -13,335,062, a change of -1,794,383.
- Net loss of 2,492,207 reduced equity.
- New share issuances of 13,707 increased equity.
- Other factors increased equity by 684,117.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-2.49 Million | -18.69% |
| Share Issuances | €13.71K | +0.1% |
| Other Changes | €684.12K | +5.13% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares IMAGIN MEDICAL INC.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-09-30 | €-1.25 | €0.00 | x |
| 2022-09-30 | €-1.23 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently IMAGIN MEDICAL INC. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | €-10.32 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-1.16 Million |
Industry Comparison
This section compares IMAGIN MEDICAL INC.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $48,854,925,736
- Average return on equity (ROE) among peers: -45.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IMAGIN MEDICAL INC. (DPD3) | €- | 0.00% | N/A | $6.33K |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $12.27 Billion | 14.01% | 0.69x | $140.36K |
| BIORETEC OY (0TN) | $4.34 Million | -138.72% | 0.98x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $464.53 Billion | 11.55% | 0.43x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $554.62 Million | 29.12% | 0.16x | $711.77 Million |
| HeraMED Limited (1I4) | $2.77 Million | -198.14% | 0.62x | $28.30 Million |
| Medtronic PLC (2M6) | $6.43 Billion | 15.30% | 0.70x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $1.86 Billion | -10.94% | 0.43x | $324.05 Million |
| AVITA Medical Inc (51KB) | $20.86 Million | -118.03% | 0.23x | $172.49 Million |
| BRAINCOOL AB (5YL) | $116.23 Million | -39.24% | 0.15x | $21.56 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.75 Billion | -16.50% | 0.09x | $107.57 Million |
About IMAGIN MEDICAL INC.
Imagin Medical Inc., a urologic oncology company, focuses on the research, development, and commercialization of medical devices in the bio-chemistry industry. It offers the i/Blue Imaging System, which detects bladder cancer with advanced proprietary optics and light sensors; and enCage Coil, a disposable and focal therapy precision ablation device for use in the treatment of prostate cancer. Th… Read more